Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

12.57 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,305
Open 12.57
Bid (Size) 12.60 (3)
Ask (Size) 12.77 (1)
Prev. Close 12.57
Today's Range 12.57 - 12.57
52wk Range 3.210 - 24.79
Shares Outstanding 52,051,405
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
The Week In Charts - Becoming A Successful Trader
Dave discusses various topics, including intra-day trading and trading opening gap reversals, the current stock market conditions, and his two cents on your favorite stock picks. 
Via Talk Markets

Performance

YTD
+59.11%
+59.11%
1 Month
+108.11%
+108.11%
3 Month
+143.60%
+143.60%
6 Month
+101.12%
+101.12%
1 Year
+0.88%
+0.88%

More News

Read More
Expert Ratings for Fulcrum Therapeutics
Via Benzinga
Why Fulcrum Therapeutics Shares Are Falling
Via Benzinga
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
Looking Into Fulcrum Therapeutics's Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
$3.4 Million Bet On CrowdStrike Holdings? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
Fulcrum Therapeutics Announces CEO Transition
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
Fulcrum Therapeutics Earnings Preview
Via Benzinga
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
From Fulcrum Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
Why Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.